Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab-Reference-Cited by-同舟云学术

Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab

Published:2020-04 Issue: Volume:112 Page:104587
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Derzi Mazin,Shoieb Ahmed M.,Ripp Sharon L.,Finch Gregory L.,Lorello Leslie G.,O'Neil Shawn P.,Radi Zaher,Syed Jameel,Thompson Matthew S.,Leach Michael W.

Funder

Food and Drug Administration

Pfizer

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference24 articles.

1. Humira (adalimumab) prescribing information,2002

2. Summary of Product Characteristics;AbbVie,2009

3. Cellular mechanisms of TNF function in models of inflammation and autoimmunity;Apostolaki;Curr. Dir. Autoimmun.,2010

4. Pharmacokinetic and toxicology comparator testing of biosimilar drugs - assessing need;Baldrick;Regul. Toxicol. Pharmacol.,2017

5. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans;Bugelski;Curr. Opin. Mol. Therapeut.,2004

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh;Discover Applied Sciences;2024-02-28

2. Protein Therapeutics;Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology;2023

3. Biosimilar antibodies;Formulation of Monoclonal Antibody Therapies;2023

4. Biosimilars approved for psoriasis treatment in Europe;PONS - medicinski casopis;2023

5. Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh;2022-12-28